Harrell Investment Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.93M Sell
31,506
-320
-1% -$68.8K 1.72% 13
2026
Q1
$6.92M Buy
31,826
+2,150
+7% +$477K 1.65% 16
2025
Q4
$6.78M Sell
29,676
-751
-2% -$171K 1.6% 15
2025
Q3
$7.05M Sell
30,427
-2,272
-7% -$463K 1.66% 15
2025
Q2
$6.07M Buy
32,699
+31,163
+2,029% +$5.79M 1.54% 18
2025
Q1
$322K Hold
1,536
0.1% 84
2024
Q4
$273K Hold
1,536
0.08% 85
2024
Q3
$303K Sell
1,536
-168
-10% -$31.4K 0.09% 81
2024
Q2
$292K Sell
1,704
-175
-9% -$29K 0.09% 84
2024
Q1
$342K Sell
1,879
-202
-10% -$34.8K 0.1% 76
2023
Q4
$323K Hold
2,081
0.1% 82
2023
Q3
$309K Hold
2,081
0.11% 81
2023
Q2
$280K Buy
2,081
+168
+9% +$24.6K 0.1% 83
2023
Q1
$309K Hold
1,913
0.11% 79
2022
Q4
$309K Hold
1,913
0.12% 83
2022
Q3
$257K Hold
1,913
0.11% 86
2022
Q2
$293K Sell
1,913
-64
-3% -$9.78K 0.12% 82
2022
Q1
$321K Hold
1,977
0.11% 87
2021
Q4
$268K Buy
1,977
+2
+0.1% +$236 0.08% 89
2021
Q3
$213K Hold
1,975
0.07% 98
2021
Q2
$222K Hold
1,975
0.07% 97
2021
Q1
$213K Buy
+1,975
New +$211K 0.08% 98

Other funds holding ABBV

Harrell Investment Partners's ABBV Position: Q2 2026 in Review

Harrell Investment Partners reduced its AbbVie (ABBV) stake by 1% in Q2 2026, selling an estimated $68.8K and leaving 31,506 shares worth $7.93M. The position accounts for 1.72% of the portfolio, ranked #13.

Harrell Investment Partners first reported a position in ABBV in Q1 2021 and has held it in 22 quarters since. 1,316 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Harrell Investment Partners held 31,506 shares of AbbVie worth $7.93M as of Q2 2026.
  • Harrell Investment Partners sold 320 AbbVie shares in Q2 2026, an estimated $68.8K.
  • AbbVie made up 1.72% of Harrell Investment Partners's portfolio in Q2 2026, its #13 holding.
  • Harrell Investment Partners first reported a position in AbbVie in Q1 2021 and has held it in 22 quarters since.
  • 1,316 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Harrell Investment Partners's 13F filing for Q2 2026, filed 9 Jul 2026.